Cov-2Antibody Test Igm Antibody

Description: This kit adopts the sandwich method and the technical principle of colloidal gold immunochromatography to qualitative determine the SARS-CoV-2 antigen. During the test, the sample is dropped into the sample well, and chromatography is performed under the capillary effect. The SARS-CoV-2 antigen in the sample combined with the colloidal goldlabeled SARS-CoV-2 monoclonal antibody I, and then spread to the test area. It is captured by another coated antibody (SARS-CoV-2 monoclonal antibody II), to form a complex and gather in the test area (T line). The quality control area is coated with the goat antimouse antibody, and the colloidal gold-labeled antibody is captured to form a complex and aggregate in the quality control area (C line). If the C line does not show color, it indicates that the result is invalid, and this sample needs to be tested again.

Description: This product is used for in vitro qualitative detection of SARS-CoV-2 antigen in human oropharyngeal swabs, nasal swabs and nasopharyngeal swabs. It is helpful as an aid in the screening of early mild, asymptomatic, or acute patients for identification of SARS-CoV-2 infection.

Description: The SARS-CoV-2 Rapid Antigen Test is a lateral fl ow rapid chromatographic immunoassay for the qualitative detection of nucleocapsid antigen to SARS-CoV-2 present in human nasal samples. This test is intended for use as an aid in detection of SARS-CoV-2 infection in individuals suspected of COVID-19 with clinical symptoms onset within 5 days. Results are for the identification of SARS-CoV-2 nucleocapsid antigen. Antigen is generally detectable in human nasal swab samples during the acute phase of infection. Positive results indicate the presence of viral antigens, but clinical correlation with patient history and other diagnostic information is necessary to determine infection status. Positive results do not rule out bacterial infection or co- infection with other viruses. The agent detected may not be the definite cause of disease. Negative results should be treated as presumptive, and do not rule out SARS-CoV-2 infection and should not be used as the sole basis for treatment or patient management decisions, including infection control decisions. Negative results should be considered in the context of a patient’s recent exposures, history and the presence of clinical signs and symptoms consistent with COVID-19, and confirmed with a molecular assay, if necessary, for patient management. The SARS-CoV-2 Rapid Antigen Test is intended for use in laboratory or POC settings by healthcare professionals, or self-collection under the supervision of a healthcare worke

Description: ELISA based test for quantitative detection of ZP(Anti-Zona Pellucida Antibody IgM)

Description: ELISA based test for quantitative detection of TA(Anti-Trophoblast Membrane Antibody IgM)

Description: ELISA based test for quantitative detection of RSV (Respiratory Syncytial Virus Antibody IgM)

Description: ELISA based test for quantitative detection of HSV-?(Herpes Simplex Virus ?Antibody IgM)

Description: ELISA based test for quantitative detection of EM Anti-endometrial Ab IgM

Description: COVID-19 IgG/IgM Rapid Test (Serum/Plasma/Whole Blood) is a qualitative membrane-based immunoassay for the detection of COVID-19 antibodies in serum, plasma, or whole blood. This test consists of two test lines, an IgG line and an IgM line, which is pre-coated with two mouse anti-human monoclonal antibodies separately. During testing, the sample reacts with COVID-19 antigen-coated on conjugated pad. As the complex continues to travel up the strip, the anti-COVID-19 IgM antibodies are bound on the IgM line, and the anti-COVID-19 IgG antibodies are bound on the IgG line. The control(C)line appears when sample has flowed through the strip. The presence of anti-COVID-19 IgM and/or IgG will be indicated by a visible test line in the IgM and IgG region. To serve as a procedural control, the control line should always appear if the test procedure is performed properly and the reagents are working as intended.

Description: ELISA based test for quantitative detection of HCG?Anti-Human Chorionic Gonadotrophin Antibody IgM)

Description: ELISA based test for quantitative detection of HAV-IgM CE Hepatitis A IgA Antibody

Description: ELISA based test for quantitative detection of EHF (Epidemic Hemorrhagic Fever Virus Antibody IgM)

Description: ELISA based test for quantitative detection of HBcAb-IgM hepatitis B core IgG antibody

Description: A sandwich quantitative ELISA assay kit for detection of Bovine Immunoglobulin M (IgM) in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids.

Description: A sandwich quantitative ELISA assay kit for detection of Bovine Immunoglobulin M (IgM) in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids.

Description: A sandwich quantitative ELISA assay kit for detection of Chicken Immunoglobulin M (IgM) in samples from serum, plasma or other biological fluids.